Table 1 Baseline demographic and clinical characteristics of the 39 enrolled patients.
Characteristics | No. of Patients (%) n = 39 |
|---|---|
Age (years) | |
Median (range) | 55 (29-73) |
<60 | 21 (53.8%) |
≥60 | 18 (46.2%) |
Sex | |
Male | 25 (64.1%) |
Female | 14 (35.9%) |
History | |
DLBCL-nos | 31 (79.4%) |
DLBCL-Unclassified | 1 (2.6%) |
HGBL-DHL | 1 (2.6%) |
MCL | 3 (7.4%) |
PMLBCL | 1 (2.6%) |
tFL | 2 (5.1%) |
Disease stage at study entry | |
I or II | 13 (33.3%) |
III or IV | 26 (66.7%) |
IPI score | |
0-1 | 6 (15.4%) |
2-3 | 21 (53.8%) |
4-5 | 12 (30.8%) |
ECOG score | |
0-1 | 23 (58.9%) |
2-3 | 16 (41.0%) |
Extranodal organ involvement | |
Yes | 25 (64.1%) |
No | 14 (35.9%) |
No.of previous lines of antineoplastic therapy | |
Median (range) | 2 (1-6) |
1 | 4 (10.2) |
2 | 15 (38.5) |
3-6 | 20 (51.3%) |
No. of prior treatment regimen | |
Median (range) | 9 (4-43) |
<10 | 21 (53.8%) |
≥10 | 18 (46.2%) |
Prior target therapy or ASCT | |
BTK inhibitor | 5 (12.8%) |
ASCT | 3 (7.7%) |
Neither BTK inhibitor nor ASCT | 31 (79.5%) |
Refractory or Relapse | |
Refractory | 19 (51.3%) |
Relapse | 20 (48.7%) |
Bulky disease (%)a | |
Yes | 11 (28.20% |
No | 28 (71.79%) |
